Pharmagreen Biotech Inc
Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. The company's primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. It also provides consulting services for plant genetic selection, tissue … Read more
Pharmagreen Biotech Inc (PHBI) - Total Assets
Latest total assets as of June 2025: $96.60K USD
Based on the latest financial reports, Pharmagreen Biotech Inc (PHBI) holds total assets worth $96.60K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmagreen Biotech Inc - Total Assets Trend (2008–2024)
This chart illustrates how Pharmagreen Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmagreen Biotech Inc - Asset Composition Analysis
Current Asset Composition (September 2024)
Pharmagreen Biotech Inc's total assets of $96.60K consist of 9.0% current assets and 91.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.3% |
| Accounts Receivable | $585.00 | 0.6% |
| Inventory | $7.97K | 8.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Pharmagreen Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmagreen Biotech Inc's current assets represent 9.0% of total assets in 2024, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 100.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 8.2% of total assets.
Pharmagreen Biotech Inc Competitors by Total Assets
Key competitors of Pharmagreen Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Pharmagreen Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharmagreen Biotech Inc generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pharmagreen Biotech Inc is currently not profitable relative to its asset base.
Pharmagreen Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.00 | 0.08 |
| Quick Ratio | 0.03 | 0.00 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.57 Million | $ -2.33 Million | $ -2.90 Million |
Pharmagreen Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Pharmagreen Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 10.24 |
| Asset Growth Rate (YoY) | -19.6% |
| Total Assets | $97.68K |
| Market Capitalization | $1.00 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Pharmagreen Biotech Inc's assets at a significant premium ( 10.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Pharmagreen Biotech Inc's assets decreased by 19.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharmagreen Biotech Inc (2008–2024)
The table below shows the annual total assets of Pharmagreen Biotech Inc from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $97.68K | -19.65% |
| 2023-09-30 | $121.57K | -41.83% |
| 2022-09-30 | $208.97K | -43.99% |
| 2021-09-30 | $373.08K | +40.13% |
| 2020-09-30 | $266.25K | -57.76% |
| 2019-09-30 | $630.27K | +40.24% |
| 2018-09-30 | $449.42K | +11331.99% |
| 2017-09-30 | $3.93K | -87.16% |
| 2008-09-30 | $30.62K | -- |